RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

study id #: NCT04571970

condition: Mucopolysaccharidosis Type II (MPS II)

status: Recruiting

purpose:

RGX-121 is a gene therapy which is designed to deliver a functional copy of the iduronate-2-sulfatase (IDS) gene to the central nervous system. This study is a phase I/II study to determine whether RGX-121 is safe, well tolerated, and potentially effective in children five years of age and over who have severe MPS II.

intervention: RGX-121

results: https://clinicaltrials.gov/ct2/show/results/NCT04571970

last updated: February 26, 2022

start date: March 11, 2021

estimated completion: September 2023

last updated: September 28, 2021

phase of development: Phase 1/Phase 2

size / enrollment: 6

study description: MPS II is a rare X-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase (IDS) gene. Enzyme replacement therapy (ERT) with recombinant idursulfase (ELAPRASE®) is the only approved product for the treatment of Hunter syndrome; however, ERT as currently administered does not cross the blood brain barrier and is therefore unable to address the unmet need in MPS II patients with CNS (neurocognition and behavior) involvement. RGX-121 is designed to deliver a healthy gene to cells in the CNS and iduronate-2-sulfatase (I2S) may then be secreted by transduced cells which may cross-correct non-transduced cells by taking up the functional enzyme. This is a Phase I/II, multicenter, open-label, single arm study of RGX-121. Approximately 6 children (≥ 5 years to < 18 years of age) who have severe (neuronopathic) MPS II could be enrolled into a single dose cohort and will receive a single dose of RGX-121 administered by IC or ICV injection. Safety will be the primary focus for the initial 24 weeks after treatment (primary study period). Following completion of the primary study period, participants will continue to be assessed (safety and efficacy) for up to a total of 104 weeks following treatment with RGX-121.

primary outcomes:

• Number of participants with treatment-related adverse events and serious adverse events
  Number of participants with treatment-related adverse events and serious adverse events as assessed by CTCAE (Version 5.0)
• 24 Weeks
  

secondary outcomes:

• Number of participants with treatment-related adverse events and serious adverse events
  104 Weeks
• Biomarkers
  Baseline, Week 1, Week 2, Week 4, Week 12, Week 24, Week 38, Week 52, Week 64, Week 78, Week 104
• Biomarkers
  Baseline, Week 1, Week 2, Week 4, Week 12, Week 24, Week 38, Week 52, Week 64, Week 78, Week 104
• Change in neurodevelopmental parameters
  Baseline, Week 52, Week 104
• Change in neurodevelopmental parameters
  Baseline, Week 52, Week 104
• Change in neurodevelopmental parameters
  Baseline, Week 24, Week 52, Week 78, Week 104

inclusion criteria:

Inclusion Criteria:

Meets any of the following criteria:

Has a documented diagnosis of MPS II AND a neurocognitive testing score ≤ 1 ½ standard deviation (SD) from the test normative mean (BSID-III: 77 and MSEL Visual Reception: 35), OR
Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (BSID-III Cognitive or MSEL Visual Reception), OR
Has a relative clinically diagnosed with neuronopathic MPS II who has the same IDS mutation as the participant AND the participant in the opinion of a geneticist has inherited a neuronopathic form of MPS II, OR
Has documented mutation(s) in IDS that in the opinion of a geneticist is known to result in a neuronopathic phenotype AND in the opinion of a clinician has a neuronopathic form of MPS II

exclusion criteria: Criteria:

Has contraindications for intracisternal injection, intracerebroventricular injection, or lumbar puncture
Has contraindications for immunosuppressive therapy
Has any neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
Has had prior treatment with an AAV-based gene therapy product
If receiving ELAPRASE® via intrathecal (IT) administration, must agree to discontinue IT idursulfase for the duration of the study
Has experienced a serious hypersensitivity reaction to intravenous (IV) ELAPRASE®
Is currently failing to respond to idursulfase (ELAPRASE®) IV due to neutralizing anti-idursulfase antibodies
Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing of the ICF, whichever is longer
Has a platelet count <100,000 per microliter (µL), absolute neutrophil count <1.0 × 103/µL, or aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at screening unless the participant has a previously known history of Gilbert's syndrome

sponsor: Regenxbio Inc.

contacts: Patient Advocacy, (866) 860-0117, MPSII@regenxbio.com

trial center locations: United States,Canada

• United States, California
  University of California San Francisco, Benioff Children’s Hospital
  Dr. Paul Harmatz, 925-639-6321, Jill.nicholas@ucsf.edu
  
  
• Canada, Quebec
  McGill University Heath Center
  Dorothy McKelvey, 514-934-1934, dorothy.mckelvey@muhc.mcgill.ca